The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Personalized approach for response prediction and treatment management for non-small cell lung cancer patients based on a liquid biopsy.
 
Yuval Shaked
Leadership - Oncohost; Remedycell
Stock and Other Ownership Interests - Oncohost; Remedycell
Consulting or Advisory Role - Oncohost
Patents, Royalties, Other Intellectual Property - Oncohost
 
Michal Harel
Employment - Oncohost
 
Coren Lahav
Employment - Oncohost
 
Ben Yellini
Employment - Oncohost
 
Ella Tepper
No Relationships to Disclose
 
Ido Wolf
Honoraria - AstraZeneca; BMS Brazil; Novartis; Roche
 
Tatiana Harkovsky
No Relationships to Disclose
 
Raya Leibowitz
Consulting or Advisory Role - Oncohost
 
Maya Gottfried
No Relationships to Disclose
 
Mahmud Abu-Amana
No Relationships to Disclose
 
Rivka Katzenelson
No Relationships to Disclose
 
Abed Agbarya
No Relationships to Disclose
 
Mor Moskovitz
No Relationships to Disclose
 
Michal Lotem
Consulting or Advisory Role - Oncohost
 
Adva Levy-Barda
No Relationships to Disclose
 
Alona Zer
Stock and Other Ownership Interests - Nixio
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Oncotest/Rhenium; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Ina Koch
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; EMD Serono; Flame Biosciences; Genentech/Roche; Geneplus; GlaxoSmithKline; Gritstone Bio; Intellisphere; Janssen; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Novocure; OncoCyte; Oncohost; Regeneron; Roche China; Sanofi; Seagen
Research Funding - Bristol-Myers Squibb
 
Adam P. Dicker
Stock and Other Ownership Interests - Oncohost
Consulting or Advisory Role - Accordant; Alcimed; CVS; Cybrexa Therapeutics; Deallus; EMD Serono; Genentech; Hengrui Pharmaceutical; IBA; Janssen; Oncohost; Orano Med; Roche; Third Bridge
Patents, Royalties, Other Intellectual Property - We recently filed a patient "DOPED BEO COMPOUNDS FOR OPTICALLY STIMULATED LUMINESCENCE (OSL) AND THERMOLUMINESCENCE (TL) RADIATION DOSIMETRY"
Expert Testimony - Wilson Sonsini
Travel, Accommodations, Expenses - Oncohost
Other Relationship - European Commission
(OPTIONAL) Uncompensated Relationships - Dreamit Ventures; Google
 
Petros Christopoulos
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); Roche (Inst); Takeda (Inst)